Cargando…
Pharmacotherapy for multidrug resistant tuberculosis
The current global concern in the treatment of tuberculosis (TB) is the emergence of resistance to the two most potent drugs namely, isoniazid and rifampicin. Emergence of multidrug resistance tuberculosis (MDR-TB) is now a health problem faced by most of the developing countries as well as develope...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356975/ https://www.ncbi.nlm.nih.gov/pubmed/22629081 http://dx.doi.org/10.4103/0976-500X.95502 |
_version_ | 1782233618407489536 |
---|---|
author | Chhabra, Naveen Aseri, M. L. Dixit, Ramakant Gaur, S. |
author_facet | Chhabra, Naveen Aseri, M. L. Dixit, Ramakant Gaur, S. |
author_sort | Chhabra, Naveen |
collection | PubMed |
description | The current global concern in the treatment of tuberculosis (TB) is the emergence of resistance to the two most potent drugs namely, isoniazid and rifampicin. Emergence of multidrug resistance tuberculosis (MDR-TB) is now a health problem faced by most of the developing countries as well as developed countries across the globe. MDR-TB is a man-made disease that is caused by improper treatment, inadequate drug supplies, and poor patient supervision. HIV infection and AIDS have been implicated as important cause for this. The review of a published literature suggests that the most powerful predictor of treatment of MDR-TB is a history of treatment of TB. Although the treatment is efficacious, there are also a number of adverse effects caused by drugs used in the treatment of MDR-TB. |
format | Online Article Text |
id | pubmed-3356975 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-33569752012-05-24 Pharmacotherapy for multidrug resistant tuberculosis Chhabra, Naveen Aseri, M. L. Dixit, Ramakant Gaur, S. J Pharmacol Pharmacother Educational Forum The current global concern in the treatment of tuberculosis (TB) is the emergence of resistance to the two most potent drugs namely, isoniazid and rifampicin. Emergence of multidrug resistance tuberculosis (MDR-TB) is now a health problem faced by most of the developing countries as well as developed countries across the globe. MDR-TB is a man-made disease that is caused by improper treatment, inadequate drug supplies, and poor patient supervision. HIV infection and AIDS have been implicated as important cause for this. The review of a published literature suggests that the most powerful predictor of treatment of MDR-TB is a history of treatment of TB. Although the treatment is efficacious, there are also a number of adverse effects caused by drugs used in the treatment of MDR-TB. Medknow Publications & Media Pvt Ltd 2012 /pmc/articles/PMC3356975/ /pubmed/22629081 http://dx.doi.org/10.4103/0976-500X.95502 Text en Copyright: © Journal of Pharmacology and Pharmacotherapeutics http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Educational Forum Chhabra, Naveen Aseri, M. L. Dixit, Ramakant Gaur, S. Pharmacotherapy for multidrug resistant tuberculosis |
title | Pharmacotherapy for multidrug resistant tuberculosis |
title_full | Pharmacotherapy for multidrug resistant tuberculosis |
title_fullStr | Pharmacotherapy for multidrug resistant tuberculosis |
title_full_unstemmed | Pharmacotherapy for multidrug resistant tuberculosis |
title_short | Pharmacotherapy for multidrug resistant tuberculosis |
title_sort | pharmacotherapy for multidrug resistant tuberculosis |
topic | Educational Forum |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3356975/ https://www.ncbi.nlm.nih.gov/pubmed/22629081 http://dx.doi.org/10.4103/0976-500X.95502 |
work_keys_str_mv | AT chhabranaveen pharmacotherapyformultidrugresistanttuberculosis AT aseriml pharmacotherapyformultidrugresistanttuberculosis AT dixitramakant pharmacotherapyformultidrugresistanttuberculosis AT gaurs pharmacotherapyformultidrugresistanttuberculosis |